Margaret S. Lucas

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

John C. Byrd, Timothy J. Murphy, Robin Howard et al. · Journal of Clinical Oncology · 2001 · 511 citations

Pharmacy, Oncology, Pharmacokinetics +15

<i>BTK</i>^C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 471 citations

Medicine, Hematology, Oncology +16

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn et al. · Blood · 2004 · 403 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Kerry A. Rogers, Ying Huang, Amy S. Ruppert et al. · Blood · 2018 · 107 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, Ying Huang, Amy S. Ruppert et al. · Journal of Clinical Oncology · 2020 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17